Pro forma revenues of the newly enlarged group were up 13.1% at US$154.1mln in the year just gone as it reported that a strong end to 2019 carried on into 2020.
Amryt Pharma 'doing very well with strong cash and recurring revenues'
Quick facts: Amryt Pharma PLC
Price: 210 GBX
Market Cap: £332.85 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE